Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Thomas A Zanardi"'
Autor:
Colby S Shemesh, Rosie Z Yu, Hans J Gaus, Sarah Greenlee, Noah Post, Karsten Schmidt, Michael T Migawa, Punit P Seth, Thomas A Zanardi, Thazha P Prakash, Eric E Swayze, Scott P Henry, Yanfeng Wang
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Triantennary N-acetyl galactosamine (GalNAc3) is a high-affinity ligand for hepatocyte-specific asialoglycoprotein receptors. Conjugation with GalNAc3 via a trishexylamino (THA)-C6 cluster significantly enhances antisense oligonucleotide (ASO) potenc
Externí odkaz:
https://doaj.org/article/1de8c3f8738147bdba5db5c61c7a342f
Autor:
Shuling Guo, Birgit Korbmacher, Jeffrey A Engelhardt, Mariam Aghajan, Laura Boone, Thomas A. Zanardi, Scott P. Henry, Sebastien A. Burel, Bobby Prill, Yanfeng Wang
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 377:51-63
Cellular uptake of antisense oligonucleotides (ASOs) is one of the main determinants of in vivo activity and potency. A significant advancement in improving uptake into cells has come through the conjugation of ASOs to triantenarry N-acetyl-galactosa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6248f46f00d8260acbb2747c654e42a6
https://doi.org/10.1124/jpet.120.000222
https://doi.org/10.1124/jpet.120.000222
Autor:
Brett P. Monia, Steven G. Hughes, Marshelle S. Warren, Jason D. Ferrone, Gwendolyn E. Kaeser, Eugene Schneider, A. Robert MacLeod, Nicholas J. Viney, Brenda F. Baker, Alexey S. Revenko, Frederick Derosier, Gourab Bhattacharjee, Nguyen C. Pham, Thomas A. Zanardi
Publikováno v:
Nucleic Acid Therapeutics. 29:82-91
Kallikrein is the key contact system mediator responsible for the conversion of high-molecular-weight kininogen into the inflammatory vasodilator peptide bradykinin, a process regulated by C1-esterase inhibitor (C1-INH). In hereditary angioedema (HAE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::969051625899292f6463ecc560f45748
https://doi.org/10.1089/nat.2018.0754
https://doi.org/10.1089/nat.2018.0754
Autor:
Alexander J. Szalai, Mark A. McCrory, Dongqi Xing, Fadi G. Hage, Andrew Miller, Suzanne Oparil, Yiu-Fai Chen, Michelle Mazzone, Richard Early, Scott P. Henry, Thomas A. Zanardi, Mark J. Graham, Rosanne M. Crooke
Publikováno v:
Mediators of Inflammation, Vol 2014 (2014)
Raised blood C-reactive protein (CRP) level is a predictor of cardiovascular events, but whether blood CRP is causal in the disease process is unknown. The latter would best be defined by pharmacological inhibition of the protein in the context of a
Externí odkaz:
https://doaj.org/article/1353b401cb894bb4a6035781bd29725d
Autor:
Thomas A, Zanardi, Birgit, Korbmacher, Laura, Boone, Jeffrey A, Engelhardt, Yanfeng, Wang, Sebastien, Burel, Bobby, Prill, Mariam, Aghajan, Shuling, Guo, Scott P, Henry
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 377(1)
Cellular uptake of antisense oligonucleotides (ASOs) is one of the main determinants of in vivo activity and potency. A significant advancement in improving uptake into cells has come through the conjugation of ASOs to triantenarry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8570ade61e834d278421b8b04acb6d94
https://pubmed.ncbi.nlm.nih.gov/33431610
https://pubmed.ncbi.nlm.nih.gov/33431610
Autor:
Lijiang Shen, David Serota, Shin-Young Park, Yunlip Kim, Tae-Won Kim, Scott P. Henry, Thomas A. Zanardi, Chris Papagiannis
Publikováno v:
Nucleic Acid Therapeutics. 28:233-241
Advances in antisense oligonucleotide (ASO) chemistry and screening have enabled the design and selection of molecules that are optimized for a particular therapeutic application in terms of both potency and tolerability. The most-well studied of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e80347a09bd5880bea4914003221101
https://doi.org/10.1089/nat.2017.0706
https://doi.org/10.1089/nat.2017.0706
Autor:
Jason D, Ferrone, Gourab, Bhattacharjee, Alexey S, Revenko, Thomas A, Zanardi, Marshelle S, Warren, Frederick J, Derosier, Nicholas J, Viney, Nguyen C, Pham, Gwendolyn E, Kaeser, Brenda F, Baker, Eugene, Schneider, Steven G, Hughes, Brett P, Monia, A Robert, MacLeod
Publikováno v:
Nucleic Acid Therapeutics
Kallikrein is the key contact system mediator responsible for the conversion of high-molecular-weight kininogen into the inflammatory vasodilator peptide bradykinin, a process regulated by C1-esterase inhibitor (C1-INH). In hereditary angioedema (HAE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b54043aab3722f9df30ce8645b4f7232
https://pubmed.ncbi.nlm.nih.gov/30817230
https://pubmed.ncbi.nlm.nih.gov/30817230
Autor:
Mark J. Graham, Rosie Z. Yu, Eric E. Swayze, Rudy Gunawan, Shannon Hall, Richard S. Geary, Jennifer Burkey, Noah Post, Scott P. Henry, Thomas A. Zanardi, Thazha P. Prakash, Punit P. Seth, Yanfeng Wang, Tae-Won Kim
Publikováno v:
Nucleic acid therapeutics. 26(6)
Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency due to receptor-mediated uptake into hepatocyte. The disposition and pharmacokinetics of ISIS 681257, a GalNAc3-conjugated ASO, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb5f918c111986a3c9c29a660b44550
https://pubmed.ncbi.nlm.nih.gov/27500733
https://pubmed.ncbi.nlm.nih.gov/27500733
Autor:
Diana Auyeung, Patrick B. Lappin, Scott P. Henry, Robert A. Fey, Thomas A. Zanardi, Mark Johnson, Arthur A. Levin
Publikováno v:
Toxicology. 301:13-20
The primary target organ for uptake of systemically administered phosphorothioate oligonucleotides is the kidney cortex and the proximal tubular epithelium in particular. To determine the effect of oligonucleotide uptake on renal function, a detailed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9087b267403a9445785ed072b0c80a4
https://doi.org/10.1016/j.tox.2012.06.005
https://doi.org/10.1016/j.tox.2012.06.005
Autor:
Thomas A. Zanardi, Scott P. Henry, Kaushik Chakravarty, Rosie Z. Yu, Su-Cheol Han, Eun Ju Jeong, Soyub Rime
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 343:489-496
ISIS 388626, a 2'-methoxyethyl (MOE)-modified antisense oligonucleotide (ASO) that targets human sodium glucose cotransporter 2 (SGLT2) mRNA, is in clinical trials for the management of diabetes. SGLT2 plays a pivotal role in renal glucose reabsorpti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcaafc89cbfc4fa0a035758b9df16205
https://doi.org/10.1124/jpet.112.197426
https://doi.org/10.1124/jpet.112.197426